SCHEMBL14125

SCHEMBL14125

COc1ccc2nc(Nc3nc(=O)c(-c4ccc(CN(CCCN)CCCN)c(F)c4)c[nH]3)[nH]c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RAB9A P51151 1/20 0.35
BDKRB1 P46663 1/20 0.35
AMY1A P0DUB6 3/20 0.34
IDH2 P48735 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
ABL1 P00519 1/20 0.33
DRD3 P35462 1/20 0.33
FLT3 P36888 1/20 0.33
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13995 0.90 BDKRB1 (0.34) ALDH1A1BDKRB1HPGDABL1
SCHEMBL14853493 0.88 HDAC11 (0.33) BDKRB1
SCHEMBL14853447 0.87 BDKRB1 (0.41) ALDH1A1TP53SMN1; SMN2RAB9ABDKRB1
SCHEMBL14153 0.82
SCHEMBL17354286 0.79 S1PR1 (0.33) SMN1; SMN2BDKRB1
SCHEMBL13897 0.78 HDAC11 (0.34)
SCHEMBL17486577 0.77 HDAC11 (0.33) BDKRB1
SCHEMBL17354222 0.76 MAPT (0.39) ALDH1A1RAB9ALMNAKMT2AFLT3
SCHEMBL13887 0.76 TP53 (0.35) ALDH1A1TP53SMN1; SMN2RAB9ABDKRB1
SCHEMBL14850243 0.76 RET (0.34) TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845297-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2017-12-19 US disclosed
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2016-02-04 US disclosed
US-9216979-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-12-22 US disclosed
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
WO-2011047323-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090326-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT ALDH1A1 1117/4885PTGDR2 3444/4885TP53 3023/4885
US-20160031828-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT ALDH1A1 1117/4885PTGDR2 3444/4885TP53 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.